A simple mailed stool test may cut the risk of dying from colorectal cancer by nearly half, according to new Swedish research tracking more than 376,000 people for up to 14 years.
Story Snapshot
- Swedish researchers found active participation in at-home colorectal cancer screening was linked to a 43% lower risk of dying from the disease.
- The study followed 376,511 people ages 60 to 69 for up to 14 years using mailed fecal occult blood tests.
- People who were simply invited to screen, whether or not they completed it, still saw a 26% lower death risk.
- The findings appeared in JAMA Network Open and build on Sweden’s national screening program.
What The Swedish Study Actually Found
Researchers at Karolinska Institutet and Umeå University tracked 376,511 Swedish adults ages 60 to 69 for up to 14 years. Everyone in the study received a mailed screening kit at home and provided a stool sample. The team recorded 1,668 deaths from colorectal cancer during the follow-up period and compared outcomes between people who completed the test and those who did not.
After adjusting for other factors, the numbers were striking. An invitation to screening alone was tied to a 26% lower risk of colorectal cancer death. But people who actually sent in their sample saw a 43% lower risk. That gap between being invited and actually participating is the heart of this story.
Sweden runs a national program that mails a fecal immunochemical test kit to residents every two years starting at age 60. A positive result triggers a follow-up colonoscopy. The size of this dataset, combined with over a decade of tracking, gives the 43% figure real statistical weight, even though it comes from an observational cohort rather than a randomized trial.
Why Participation Numbers Often Look Better Than Invitation Numbers
Doctors who study screening programs have seen this pattern before. People who follow through on preventive tests tend to be healthier overall than those who skip them. Researchers call this healthy user bias, and it can make participation-based numbers look stronger than they truly are. That does not mean the Swedish findings are wrong. It means the 43% figure likely overstates the pure effect of the test itself, since some of that benefit comes from the kind of person who mails the kit back.
A separate large cohort study on early screening invitations found a more modest but still significant 14% drop in colorectal cancer deaths among those invited earlier. That smaller, invitation-only number may be closer to what a universal screening mandate would actually deliver, since it includes everyone offered the test, not just the motivated subset who completed it.
How This Fits Other Major Screening Trials
Sweden has also run the SCREESCO trial, comparing one-time colonoscopy against repeated stool testing. Research summarizing those results found that inviting people to stool-based testing performed about as well as colonoscopy invitations at preventing colorectal cancer deaths over ten years. That consistency across different Swedish and international studies supports a simple, practical takeaway: regular screening, in whatever form a patient will actually complete, saves lives.
A colorectal cancer screening kit showed up at your door… now what?
The Alliance, in partnership with @Cologuard, has launched a new online hub explaining why eligible adults may receive use-at-home screening tests from their health plans, how the process works, and what steps… pic.twitter.com/I0drnjd3W5
— Colorectal Cancer Alliance (@CCAlliance) September 28, 2026
Colorectal cancer remains one of the most preventable cancers when caught early, yet screening rates still lag in many countries, including the United States. The Swedish data offers a clear, common-sense message for American readers: a free or low-cost mailed test taken at home, with no sedation or hospital visit required, carries real potential to extend lives. For patients who avoid colonoscopies out of fear or inconvenience, this is a low-barrier alternative worth taking seriously.
None of this replaces a doctor’s advice on which test fits an individual’s risk level and family history. But the broader lesson holds across multiple studies and countries: screening works, participation matters most, and the biggest risk factor of all may simply be letting the kit sit unopened in a drawer.
Sources:
mindbodygreen.com, nature.com, beckersasc.com, health.harvard.edu, earth.com
